| Literature DB >> 36139074 |
Yifan Huang1,2, Ying Li1,2, Wensen Lin1,2, Shuhao Fan1,2, Haorong Chen1,2, Jiaojiao Xia1,2, Jiang Pi1,2, Jun-Fa Xu1,2.
Abstract
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb) infection, remains one of the most threatening infectious diseases worldwide. A series of challenges still exist for TB prevention, diagnosis and treatment, which therefore require more attempts to clarify the pathological and immunological mechanisms in the development and progression of TB. Circular RNAs (circRNAs) are a large class of non-coding RNA, mostly expressed in eukaryotic cells, which are generated by the spliceosome through the back-splicing of linear RNAs. Accumulating studies have identified that circRNAs are widely involved in a variety of physiological and pathological processes, acting as the sponges or decoys for microRNAs and proteins, scaffold platforms for proteins, modulators for transcription and special templates for translation. Due to the stable and widely spread characteristics of circRNAs, they are expected to serve as promising prognostic/diagnostic biomarkers and therapeutic targets for diseases. In this review, we briefly describe the biogenesis, classification, detection technology and functions of circRNAs, and, in particular, outline the dynamic, and sometimes aberrant changes of circRNAs in TB. Moreover, we further summarize the recent progress of research linking circRNAs to TB-related pathogenetic processes, as well as the potential roles of circRNAs as diagnostic biomarkers and miRNAs sponges in the case of Mtb infection, which is expected to enhance our understanding of TB and provide some novel ideas about how to overcome the challenges associated TB in the future.Entities:
Keywords: biomarkers; circular RNAs; immunity; pathology; tuberculosis
Mesh:
Substances:
Year: 2022 PMID: 36139074 PMCID: PMC9496049 DOI: 10.3390/biom12091235
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Schematic representations of several biological roles of circRNAs discussed in this article, including exonic circRNAs (EcirRNAs), intronic circRNA (ciRNAs) and exonic-intronic circRNAs (EIciRNAs). (a) CircRNAs can function as microRNA (miRNA) sponges or decoys by binding to the miRNA recognition elements (MREs) of miRNAs, thus affecting the expression of miRNA to target mRNA functions. (b) CircRNAs can function as key regulators of protein sponges or decoys by competing for the binding to the shared RNA binding protein (RBPs) binding motifs with specific RBPs. (c) CircRNAs are able to come into contact with two RBPs, and one of the proteins is often an enzyme such as E3 ubiquitin ligase, that is involved in the ubiquitination progress, which could lead to protein destabilization and degradation. (d) CircRNAs with internal ribosome entry site (IRES) elements can be translated to unique peptides. Also, circRNAs contain extensive N6-methyladenosines (m6A) modifications. For example, YTHDF3 as the m6A reader and eIF4G2 as translation initiation factor are sufficient to drive protein translation in a cap-independent fashion. (e) CircRNAs located in the nucleus can participate in regulating the expression of parental genes. For instance, circRNAs can interact with U1 snRNP and further bind to RNA polymerase II (Pol II) in the promoter region of gene to enhance the expression of parental genes. Moreover, ciRNAs can not only form a more stable R-loop with the parent gene DNA in a structure-dependent manner, but also can be degraded by RNase H1 in an R-loop-dependent manner, thus achieving transcription extension of parent genes.
Summary of all the circular RNAs that are currently reported to be involved in regulating Tuberculosis.
| Circular RNA | Function | Expression | Derived From | Targets/Signaling | AUC | Number of TB | Ref. |
|---|---|---|---|---|---|---|---|
| hsa_circ_0001204 | biomarker | down | plasma | 0.871 | 145/120 | [ | |
| hsa_circ_0001747 | biomarker | down | plasma | 0.830 | 145/120 | [ | |
| hsa_circ_0001204; | biomarker | down | plasma | 0.928 * | 145/120 | [ | |
| hsa_circ_0001953 | biomarker | up | plasma | 0.826 | 120/100 | [ | |
| hsa_circ_0009024 | biomarker | up | plasma | 0.777 | 120/100 | [ | |
| hsa_circ_0001953; hsa_circ_0009024 | biomarker | up | plasma | 0.915 * | 120/100 | [ | |
| hsa_circ_001937 | biomarker | up | PBMCs | 0.873 | 115/90 | [ | |
| hsa_circ_0043497 | biomarker | up | Mtb-infected MDMs | 0.860 | 96/85 | [ | |
| hsa_circ_0001204 | biomarker | down | Mtb-infected MDMs | 0.848 | 96/85 | [ | |
| hsa_circ_103017 | biomarker | up | PBMCs | 0.870 | 31/30 | [ | |
| hsa_circ_059914 | biomarker | up | PBMCs | 0.821 | 31/30 | [ | |
| hsa_circ_0028883 | biomarker | up | PBMCs | miR-409-5p | 0.773 | 20/20 | [ |
| hsa_circ_0005836 | biomarker | down | PBMCs | no mention | 49/45 | [ | |
| hsa_circ_0001380 | biomarker | down | PBMCs | 0.9502 | 32/31 | [ | |
| hsa_circ_103571 | biomarker | down | plasma | 0.838 | 32/29 | [ | |
| circ_051239 | biomarker | up | serum | 0.9738 | 72/30 | [ | |
| circ_029965 | biomarker | up | serum | 0.9443 | 72/30 | [ | |
| circ_404022 | biomarker | up | serum | 0.9682 | 72/30 | [ | |
| SAMD8_ | no mention | no mention | whole blood | no mention | 45/61 | [ | |
| TWF1_ | no mention | no mention | whole blood | no mention | 45/61 | [ | |
| circTRAPPC6B | miRNA sponge | down | PBMCs | miR-874-3p | 0.8609 | 32/31 | [ |
| hsa_circ_0003528 | miRNA sponge | up | plasma | miR-224-5p | no mention | 50/50 | [ |
| hsa_circ_101128 | biomarker; miRNA sponge | up | PBMCs | let-7a | 0.817 | 31/30 | [ |
| hsa_circ_0045474 | miRNA sponge | down | PBMCs | miR-582-5p | no mention | 15/15 | [ |
| circAGFG1 | miRNA sponge | up | alveolar macrophages in ATB patients | Notch | no mention | no mention | [ |
| circ_0001490 | miRNA sponge | down | Mtb-infected THP-1 macrophages; | miR-579-3p | no mention | 40/23 | [ |
| cPWWP2A | miRNA sponge | down | primary human MDMs | miR-579 | no mention | no mention | [ |
* The AUC for distinguishing TB patients when several circRNAs are used in combination.